Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that ex vivo activated immune cells would produce multiple known and
unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell
growth and differentiation. Additionally, these cells travel and home to bone marrow as well
as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may
be beneficial.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
Collaborators:
Liu Hua Qiao Hospital The 12th Guangzhou Municipal Hospital